Parc Tauli Hospital Universitari
- Address
- Parc Del Tauli 1, 08208 Sabadell, Spain
Parc Tauli Hospital Universitari - Advanced Clinical Research Center
Parc Tauli Hospital Universitari stands as a distinguished clinical research institution with extensive expertise in oncology, autoimmune diseases, and critical care medicine. The center participates in cutting-edge Phase 2 and Phase 3 international trials, focusing on innovative therapeutic approaches including immunotherapy, targeted biologics, and personalized medicine strategies across multiple therapeutic domains.
- Comprehensive oncology research including breast cancer, lung cancer, prostate cancer, bladder cancer, and colorectal cancer with emphasis on immunotherapy and targeted treatments
- Autoimmune and inflammatory conditions including psoriatic arthritis, systemic lupus erythematosus, Sjögren's disease, and inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Critical care and hepatology studies encompassing acute respiratory distress syndrome (ARDS), non-alcoholic steatohepatitis (NASH), chronic liver disease, and pancreatitis
- Neurological and rare disease research including migraine prevention, schizophrenia, and Angelman syndrome
The hospital demonstrates particular strength in combination immunotherapy trials and neoadjuvant treatment strategies, evaluating novel checkpoint inhibitors, antibody-drug conjugates, and biologics. With expertise spanning from pediatric to adult populations, Parc Tauli Hospital Universitari contributes to advancing precision medicine through biomarker-driven patient selection, liquid biopsy technologies, and multi-omics approaches. The center's research portfolio reflects a commitment to improving treatment outcomes while addressing quality of life considerations, including studies on treatment administration efficiency and patient-centered care delivery models.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 28 therapeutic areas and 15 of 393 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 378 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 91 by active trials.
- 1Novartis Pharma AG7active
lock +90 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG22trials
lock +48 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Parc Tauli Hospital Universitari
lock Showing 1 of 292 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 393 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Enzalutamide | 12 | Unknown | 2015-08-19 | 2026-03-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.